[Molecular epidemiology of cancers and precancerous conditions]. 2004

István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
Pécsi Tudományegyetem, Altalános Orvostudományi Kar, Közegészségtani Intézet, Pécs. istvan.ember@aok.pte.hu

For many years the molecular biology has been one of the most promising fields of science and its several methods have been used in practice. These new methods of molecular biology made impression on epidemiology and developed a new discipline, called molecular epidemiology. The molecular and predictive epidemiology play more and more important roles in the prevention of cancers. Early biomarkers could identify the high risk population to have the possibilities of primary preventive interventions. It uses both molecular biological methods and the elements of epidemiology. Its specificity is not high enough to establish the diagnosis but it can be used to follow the "minimal residual disease" and with markers of individual susceptibility, to assess the risk of tumors. As to the practice there are many problems because of the limited therapeutic possibilities, but the molecular and predictive epidemiology becomes an important part of medicine in the future.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018365 Neoplasm, Residual Remnant of a tumor or cancer after primary, potentially curative therapy. Minimal Residual Disease,Residual Cancer,Residual Tumor,Minimal Disease, Residual,Residual Disease, Minimal,Residual Neoplasm,Residual Tumour,Cancer, Residual,Minimal Residual Diseases,Residual Cancers,Residual Minimal Disease,Residual Minimal Diseases,Residual Neoplasms,Residual Tumors,Residual Tumours,Tumour, Residual
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
November 1973, Vrachebnoe delo,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
July 2002, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
December 1971, Bordeaux medical,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
February 1986, HNO,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
October 1968, Minerva medica,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
September 2002, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
April 1995, La Revue du praticien,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
June 1968, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
January 2010, Cancer science,
István Ember, and István Kiss, and János Sándor, and Csaba Varga, and Zoltán Gyöngyi, and Katalin Németh, and Katalin Fehér, and Péter Lukács, and Zsuzsanna Dombi
January 1985, Langenbecks Archiv fur Chirurgie,
Copied contents to your clipboard!